Author

H. Papp

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Approach:deep learning· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

F. Jakab· 3 shared A. Kuczmog· 2 shared G. Kemenesi· 2 shared M. Madai· 2 shared B. Somogyi· 1 shared B. Zana· 1 shared E. Nagy· 1 shared F. Foldes· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

F. Jakab

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Methylene Blue Is a Nonspecific Protein-Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19

S.-T. Chuang, H. Papp, A. Kuczmog, R. Eells, J. M. Condor Capcha, L. A. Shehadeh, F. Jakab, P. Buchwald

This paper shows methylene blue inhibits SARS-CoV-2 spike-ACE2 interactions and viral replication, with potential as an antiviral for COVID-19.

bioRxiv · Mar 22, 2022Pharmacology & Toxicology

Small interfering RNAs are highly effective inhibitors regarding Crimean-Congo hemorrhagic fever virus replication in vitro

F. Foldes, M. Madai, H. Papp, G. Kemenesi, B. Zana, L. Geiger, K. Gombos, B. Somogyi, I. Bock-Marquette, F. Jakab

This study identifies four siRNAs that effectively inhibit CCHFV replication in vitro by targeting all three viral genome segments.

Molecules · Dec 7, 2020Peer-reviewedMicrobiology

The Anti-histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits SARS-CoV-2 Infection in Reconstituted Human Nasal Tissue In Vitro

R. Konrat, H. Papp, V. Szijarto, T. Gesell, G. Nagy, M. Madai, S. Zeghbib, A. Kuczmog, Z. Lanszki, Z. Helyes, G. Kemenesi, F. Jakab, E. Nagy

This paper identifies azelastine, an anti-histamine drug, as a potential inhibitor of SARS-CoV-2 infection through computational repurposing and in vitro testing in human nasal tissue.

bioRxiv · Sep 15, 2020 · PreprintMicrobiology